| Project/Area Number |
26460624
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
遠藤 慎治 筑波大学, 医学医療系, 講師 (40625919)
大和 建嗣 筑波大学, 医学医療系, 研究員 (50174751)
山本 祥之 筑波大学, 附属病院, 病院講師 (00649288)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | p73 / がん / p73活性化 / ΔNp73 / iASPP / TP53変異細胞 / MDM2 |
|---|
| Outline of Final Research Achievements |
p73 has a high homology to tumor-suppressor gene p53, and acts as a translational factor like p53 in p53-mutant type cancer cells.
In this study, we evaluated the tumor growth inhibition of p73 in human tumor cell lines. p73 was induced by 5-FU or irinotecan administration in the colon cancer cells (DLD-1, HCT116). Using HCT116, the function of p73 was investigated with various inhibition of related-molecules under 5-FU exposure. As the results, p73 tumor-suppressive function was little in this cancer line regardless of harboring p53 mutation. Further studies are needed to develop a novel strategy using p73 for anticancer treatments.
|
